Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

By
Simply Wall St
Published
May 16, 2022
NasdaqGS:ALKS
Source: Shutterstock

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that Alkermes plc (NASDAQ:ALKS) does use debt in its business. But is this debt a concern to shareholders?

When Is Debt A Problem?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, plenty of companies use debt to fund growth, without any negative consequences. When we think about a company's use of debt, we first look at cash and debt together.

See our latest analysis for Alkermes

What Is Alkermes's Net Debt?

As you can see below, Alkermes had US$295.2m of debt, at March 2022, which is about the same as the year before. You can click the chart for greater detail. But it also has US$528.9m in cash to offset that, meaning it has US$233.7m net cash.

debt-equity-history-analysis
NasdaqGS:ALKS Debt to Equity History May 16th 2022

How Strong Is Alkermes' Balance Sheet?

Zooming in on the latest balance sheet data, we can see that Alkermes had liabilities of US$462.4m due within 12 months and liabilities of US$440.1m due beyond that. Offsetting this, it had US$528.9m in cash and US$270.2m in receivables that were due within 12 months. So it has liabilities totalling US$103.4m more than its cash and near-term receivables, combined.

Of course, Alkermes has a market capitalization of US$4.39b, so these liabilities are probably manageable. Having said that, it's clear that we should continue to monitor its balance sheet, lest it change for the worse. Despite its noteworthy liabilities, Alkermes boasts net cash, so it's fair to say it does not have a heavy debt load! The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine Alkermes's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

Over 12 months, Alkermes reported revenue of US$1.2b, which is a gain of 15%, although it did not report any earnings before interest and tax. That rate of growth is a bit slow for our taste, but it takes all types to make a world.

So How Risky Is Alkermes?

Although Alkermes had an earnings before interest and tax (EBIT) loss over the last twelve months, it generated positive free cash flow of US$140m. So although it is loss-making, it doesn't seem to have too much near-term balance sheet risk, keeping in mind the net cash. With revenue growth uninspiring, we'd really need to see some positive EBIT before mustering much enthusiasm for this business. For riskier companies like Alkermes I always like to keep an eye on whether insiders are buying or selling. So click here if you want to find out for yourself.

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.